

TOPIC HIGHLIGHT

Natalia A Osna, MD, PhD, Series Editor

Alcohol-induced steatosis in liver cells

Terrence M Donohue Jr

Terrence M Donohue Jr, Liver Study Unit, The Omaha Veterans Affairs Medical Center, the Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68105, United States

Supported by New Research Grant from the University of Nebraska Medical Center, the NIAAA, and Medical Research Funds from the Department of Veterans Affairs, United States

Correspondence to: Terrence M Donohue Jr, PhD, Liver Study Unit, Research Service (151), VA Medical Center, 4101 Woolworth Ave, Omaha, NE 68105, United States. tdonohue@unmc.edu

Telephone: +1-402-3468800- 93556 Fax: +1-402-4490604

Received: June 30, 2007 Revised: July 24, 2007

Fatty acid toxicity; Triglycerides; Acetaldehyde; Reactive oxygen species

Donohue TM Jr. Alcohol-induced steatosis in liver cells. *World J Gastroenterol* 2007; 13(37): 4974-4978

<http://www.wjgnet.com/1007-9327/13/4974.asp>

Abstract

Alcohol-induced fatty liver (steatosis) was believed to result from excessive generation of reducing equivalents from ethanol metabolism, thereby enhancing fat accumulation. Recent findings have revealed a more complex picture in which ethanol oxidation is still required, but specific transcription as well as humoral factors also have important roles. Transcription factors involved include the sterol regulatory element binding protein 1 (SREBP-1) which is activated to induce genes that regulate lipid biosynthesis. Conversely, ethanol consumption causes a general down-regulation of lipid (fatty acid) oxidation, a reflection of inactivation of the peroxisome proliferator-activated receptor- α (PPAR- α) that regulates genes involved in fatty acid oxidation. A third transcription factor is the early growth response-1 (Egr-1), which is strongly induced prior to the onset of steatosis. The activities of all these factors are governed by that of the principal regulatory enzyme, AMP kinase. Important humoral factors, including adiponectin, and tumor necrosis factor- α (TNF- α), also regulate alcohol-induced steatosis. Their levels are affected by alcohol consumption and by each other. This review will summarize the actions of these proteins in ethanol-elicited fatty liver. Because steatosis is now regarded as a significant risk factor for advanced liver pathology, an understanding of the molecular mechanisms in its etiology is essential for development of effective therapies.

© 2007 The WJG Press. All rights reserved.


Key words: Ethanol metabolism; Fatty liver; Sterol regulatory element binding protein; Peroxisome proliferator activated receptor; Early growth response-1;

INTRODUCTION

Fatty liver (steatosis) is the earliest, most common response of the liver to moderate or large doses (i.e. binge drinking) of alcohol as well as to chronic ethanol consumption^[1]. Steatosis was previously considered a relatively harmless side effect of heavy alcohol use. However, recent evidence now indicates that alcohol-induced fatty liver enhances susceptibility of the liver to more advanced pathology if drinking continues. Individuals with alcohol-induced steatosis are vulnerable to developing alcoholic steatohepatitis (ASH), hepatic fibrosis, cirrhosis and even hepatocellular carcinoma. Obesity, which may potentiate alcoholic fatty liver, is also considered an additional risk factor for alcoholic cirrhosis^[2] and for advanced liver disease in obese nondrinkers^[3]. The latter is most often presented clinically as nonalcoholic steatohepatitis (NASH). The reason(s) why some individuals progress from fatty liver to the more advanced stages of liver disease is not clear. The current concept adopted by many investigators is the two hit hypothesis in which the first hit is steatosis. This is followed by a second "hit" in the form of cytokine (e.g. TNF- α) production, mitochondrial dysfunction and/or oxidative stress. All three of these "hits" are widely believed to be major contributors to alcohol-induced liver injury and may compound the initial steatosis. An evolving concept that is gaining acceptance is that certain accumulated fatty acids are toxic to the liver, but that their toxicity is blunted by esterification with glycerol to form triacylglycerols (triglycerides). Thus ethanol-elicited hepatic lipid accumulation as well as that caused by dietary sources, has prompted renewed interest as a cornerstone of liver toxicity, as it may not only initiate but enhance the progression of alcoholic liver disease. This review will discuss both the metabolic and the molecular factors that contribute to ethanol induced steatosis. It will also consider the possible mechanism(s) by which liver injury is initiated to produce advanced liver pathology.

ETHANOL METABOLISM AND FATTY LIVER

The liver is the primary site of ethanol metabolism, as hepatocytes express the major ethanol metabolizing enzymes, alcohol dehydrogenase (ADH), and cytochrome P450 2E1 (CYP2E1) at higher levels than any other tissue^[4-6]. ADH, with a Michaelis constant of 1 to 2 mmol/L, catalyzes ethanol oxidation, using NAD as a coenzyme in a reaction that forms acetaldehyde and reduced NAD (i.e. NADH⁺) in reaction (1) below. This and the subsequent oxidation of acetaldehyde to acetate with the formation of another reducing equivalent of NADH⁺ in a reaction catalyzed by aldehyde dehydrogenase (ALDH) in reaction (2) below were shown to cause significant changes in cellular redox potential and provide more substrate availability for fatty acid synthesis.



Enhanced generation of reduced NAD also disrupts mitochondrial β -oxidation of fatty acids thereby diminishing the rate of lipid oxidation. This metabolic explanation for fatty liver was the prevailing concept for a number of years, but it was not sufficient to explain the rapid formation of fatty liver after acute ethanol administration. In addition, the degree of change in liver redox potential that occurs *in vivo* after chronic ethanol administration to rodents was significant but rather modest. Thus, the metabolic explanation for alcohol-induced fatty liver became insufficient to account for all changes that occurred in hepatic lipids after ethanol consumption. Later discoveries in cell signaling and characterization of specific transcription factors prompted investigations of specific factors that are operative in the pathophysiology of ethanol-induced steatosis.

UPDATED MECHANISMS OF ETHANOL-INDUCED FATTY LIVER

Enhancement of lipid synthesis by ethanol consumption

Hepatic fatty acid triglyceride and phospholipid synthesis are accelerated after acute and chronic ethanol consumption^[7]. Enhanced lipogenesis is a reflection of higher expression of lipogenic enzymes including fatty acid synthase, acyl CoA carboxylase (ACC), ATP citrate lyase (ACL), stearoyl CoA desaturase and malic enzyme.^[8,9] These enzymes are encoded by genes regulated by the transcription factor, sterol regulatory element binding protein-1 or SREBP-1.

Activation of SREBP-1 and enhanced expression of lipogenic enzymes

By activating SREBP, a member of a family of transcription factors that target genes encoding enzymes involved in cholesterol metabolism, ethanol consumption can short circuit normal hepatic lipid metabolism,

converting the liver from a lipid burning to a lipid storing organ. There are three isoforms of SREBP: SREBP-1a, 1c and 2. SREBP 1a and 1c are alternative forms of the protein encoded by the same exon. Forms 1c and 2 are principally involved in regulating fatty acid and cholesterol synthesis, respectively. All SREBP proteins reside in the endoplasmic reticulum. To function as a transcription factor, the amino terminal domain of SREBP is proteolytically cleaved from the carboxy terminal domain in the Golgi apparatus and the fragment translocates to the cell nucleus. This is accomplished by proteolytic cleavage through the action of two proteases; site-1 protease (S1P) and site-2 protease (S2P), both located in the Golgi apparatus. SREBP is initially translocated from its site in the ER to the Golgi by SREBP activating protein (SCAP). SCAP activity is sensitive to intracellular cholesterol levels and possesses a cholesterol sensing domain in its primary structure. When cholesterol levels are low, SCAP translocates SREBP from the ER to the Golgi where S1P cleaves the precursor form of SREBP, producing a membrane-bound intermediate. The intermediate is then cleaved by S2P to release the active transcription factor domain from the membrane, enabling it to bind to specific promoter elements on the DNA. Under normal circumstances, when intracellular cholesterol levels rise, SCAP activity is suppressed, thereby preventing transport and activation of SREBP by S1P and S2P. Ethanol metabolism, on the other hand, disturbs the regulatory loop of SREBP activation and causes increased cleavage of SREBP-1c, even when intracellular levels of cholesterol and/or fatty acids are high. Active SREBP-1c is detected experimentally in nuclear fractions as a -65 kDa protein, derived originally from a -125 kDa precursor. Thus, SREBP-1c has an essential function in the development of ethanol-elicited fatty liver. Nuclear fractions from livers of ethanol-fed rodents or from cultured cells that are capable of ethanol metabolism have elevated levels of the active form of SREBP-1c. A requirement for ethanol metabolism in SREBP induction has been reported using cultured cells and there is considerable evidence that the activating factor is acetaldehyde^[10]. The mechanism of ethanol-elicited SREBP-1 activation is also partly due to inhibition of the AMP-activated protein kinase (AMPK), described in greater detail below. AMPK catalyzes the phosphorylation of target enzymes, some of which are important rate-limiting enzymes in hepatic lipid metabolism. By inhibiting the activity of AMPK, ethanol relieves suppression of SREBP-1, causing its activation and increasing its levels in the nucleus.

Ethanol-elicited decline in fatty acid oxidation: Regulation of the peroxisome proliferator activated receptor alpha

Ethanol-elicited decline in fatty acid oxidation: Regulation of the peroxisome proliferator activated receptor alpha is a nuclear receptor that regulates expression of genes that possess peroxisome proliferator response elements in their promoter regions. Several such genes are those that encode fatty acid transporters, including carnitine palmitoyl transferase I, proteins involved in export,

such as apolipoprotein B, the microsomal triglyceride transfer protein, fatty acid binding protein, and acyl CoA dehydrogenase. PPAR- α interacts with the retinoid X receptor (RXR). The protein complex is activated by binding to fatty acids, thereby enhancing expression of proteins involved in the fatty acid transport and oxidation.

Ethanol administration to rodents or ethanol exposure to ethanol-metabolizing cultured cells causes a general down-regulation of PPAR- α , as reflected by reduced binding by the RXR-PPAR- α complex to a PPAR- α -specific promoter sequence^[11]. This effect of ethanol is enhanced by exposure of ethanol-treated hepatoma cells to the aldehyde dehydrogenase inhibitor, cyanamide and is abolished by the alcohol dehydrogenase inhibitor, 4-methylpyrazole. Further, RXR-PPAR- α extracted from hepatoma cells previously exposed to ethanol or acetaldehyde binds poorly to an oligonucleotide containing peroxisome proliferator response elements, indicating that acetaldehyde is responsible for the action of ethanol. It is possible that acetaldehyde, because of its ability to covalently bind proteins^[12] can form adducts with the PPAR- α transcription complex, thereby preventing its ability to bind the promoter element(s). It is noteworthy; however, that the effect at the level of transcription does not universally down-regulate all PPAR- α -regulated enzymes. *In vivo* studies have shown that the steady state level of mRNA encoding medium chain acyl CoA dehydrogenase is decreased by ethanol, but mRNAs encoding other PPAR- α -sensitive enzymes, including those mentioned above are minimally affected, unaffected, and in the case of fatty acid binding protein, actually induced by ethanol. An explanation for this, as described by You and Crabb^[13] is that the regulation of fatty acid oxidation is not solely controlled by the activities of the fatty acid oxidative enzymes. There is additional allosteric regulation of fatty acid transport into the mitochondrion by the intramitochondrial levels of malonyl CoA, which inhibits the carnitine palmitoyltransferase I (CPT I), thereby preventing transport of fatty acyl CoA derivatives into this organelle. With the concomitant up-regulation of fatty acid biosynthesis by ethanol, this is an important step in the down-regulation of fatty acid oxidation. An additional natural regulatory factor is the adipocyte hormone adiponectin. Chronic ethanol administration causes a significant reduction in circulating adiponectin, which is associated with the ethanol-elicited reduction in fatty acid oxidation^[14]. Restoration of adiponectin to ethanol-fed animals by treatment with the recombinant form of the hormone restores fatty acid oxidation to normal. Moreover, such treatment decreases the levels of TNF- α in these animals, as the hormone and the cytokine are known to regulate each other's production^[15].

It is also noteworthy that ethanol-elicited inhibition of fatty acid oxidation can be reversed, as demonstrated by experiments in which ethanol-fed animals were co-treated with the PPAR- α agonist, WY14,643. Fatty liver was blocked in these animals due to induction of PPAR- α , which, in turn, accelerated fatty acid oxidation thereby preventing ethanol-elicited fatty liver^[15]. These findings underscore the metabolic importance of fatty acid oxidation in the elimination of steatosis and emphasize

the therapeutic potential of this agent and other PPAR- α agonists as adjuncts to the natural hormone, adiponectin.

Adenosine monophosphate-activated protein kinase and alcohol-induced fatty liver

Hepatic lipid metabolism has been shown to be tightly regulated by adenosine monophosphate-activated protein kinase (AMPK). This enzyme, a heterotrimeric protein, is, itself, activated by AMP as well as by phosphorylation by another kinase, LKB-1. Elevated AMP levels are indicators of low intracellular energy charge. Therefore, when AMP activates the AMPK it down-regulates energy requiring pathways, presumably as a means of energy (ATP) conservation. Such ATP-utilizing pathways are generally biosynthetic and include lipid, RNA and protein synthesis. Conversely, AMPK activates ATP-generating catabolic pathways, such as fatty acid oxidation, the TCA cycle and glycolysis. The rate-limiting enzyme in lipid biosynthesis is the acetyl CoA carboxylase (ACC), the activity of which is down-regulated *via* phosphorylation by AMPK^[16]. ACC catalyzes the carboxylation of acetyl CoA to malonyl CoA. The latter is a potent inhibitor of lipid oxidation and its declining levels potentiate mitochondrial transport and fatty acid oxidation.

When ethanol is added to cultured hepatoma cells that oxidize ethanol, it induces transcription of an SREBP-regulated promoter and increases the levels of the mature form of SREBP-1. Both these effects are blocked by the inclusion in the culture medium of 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) or metformin, both AMPK activators^[17]. Furthermore, overexpression of AMPK in these cells blocks the ethanol-induced increase in promoter activity and SREBP protein. Exposure of cells to ethanol reduces the activity of AMPK. *In vivo* studies confirm these findings. Feeding mice an ethanol diet significantly reduces hepatic AMPK activity, while increasing the activity of the rate-limiting enzyme, ACC^[17]. At the same time, fatty acid oxidation is reduced. These findings demonstrate that AMPK regulates the ethanol-elicited SREBP-1 activation and the development of steatosis. They also demonstrate the therapeutic value of AICAR and of metformin in preventing and/or reversing fatty liver caused not only by ethanol but also by dietary induction. The latter has been demonstrated in metformin-treated leptin-deficient experimental animals^[18]. Thus the central role of AMPK in regulating these activities is well illustrated by ethanol's effect in the genesis of fatty liver.

Role of Egr-1 in ethanol-induced steatosis

Another transcription factor, early growth response-1 (Egr-1) also appears to have a role in ethanol-elicited steatosis. Egr-1, also known as nerve growth factor 1-A (NGF1-A), is an immediate early gene and transcription factor that regulates genes involved in response to cellular stress. Early work demonstrated that Egr-1 is induced in response to growth factors^[19,20]. Several genes relevant to alcohol-induced liver injury have promoter regions that bind Egr-1. Among these genes are those that encode platelet-derived growth factor (PDGF), transforming growth factor beta (TGF- β), and intercellular adhesion molecule-1 (ICAM-1)^[21]. Specifically, with regard to ethanol-induced fatty liver, Egr-1

also binds the gene encoding tumor necrosis factor alpha (TNF- α)^[22]. This latter finding is noteworthy as this cytokine is considered lipogenic, causing the activation of SREBP-1, thereby enhancing lipid biosynthesis^[23]. Perhaps the most compelling evidence for the essentiality of Egr-1 in ethanol-elicited steatosis is that reported by McMullen *et al*^[24], who showed that, in contrast to wild type mice, which develop fatty liver in response to chronic ethanol administration, that Egr-1 null mice exhibit neither hepatic steatosis nor elevated TNF- α , after four weeks of chronic ethanol feeding. These workers also reported enhanced production of Egr-1 in ethanol-fed mice treated with lipopolysaccharide (LPS), compared with similarly-treated pair-fed control mice. The data suggest that the absence of Egr-1 prevents ethanol-elicited fatty liver and reduces sensitivity to LPS. Studies by Zhou *et al*^[1] demonstrated that 90 min after an acute dose of ethanol (6 g/kg body wt), hepatic TNF- α levels rise three-fold, followed by elevated levels of hepatic triglycerides. While these investigators did not measure Egr-1, they showed a close association between elevated levels of plasma endotoxin, oxidative stress, and TNF- α in ethanol-fed mice, suggesting that endotoxin, *via* oxidative stress, stimulates the production of TNF- α . This latter may result from enhanced transcription by Egr-1.

While Egr-1 is rapidly synthesized, its levels are also regulated through degradation by the proteasome^[25]. It has been postulated that inhibition of proteasome activity by ethanol administration has a distinct role in the increase in SREBP-1 protein, which is also a proteasome substrate^[17]. Similarly, PPAR- α and RXR levels are controlled by the ubiquitin-proteasome pathway^[26,27]. So, too proteasome inhibition may also contribute to the ethanol-induced rise in Egr-1. Recent experiments in our laboratory have demonstrated that acute ethanol administration to wild type mice causes enhancement of both Egr-1 mRNA and protein levels in livers of these animals one hr after ethanol administration. These increases precede the ethanol-elicited rise in triglycerides, detected after 3 h. In cultured hepatoma cells that metabolize ethanol, overexpression of Egr-1 following transfection with an adenoviral Egr-1 expression vector, enhances triglyceride accumulation in these cells over those of control cells. Furthermore, exposure of transfected cells to ethanol causes a further rise in the level of Egr-1 with a concomitant rise in cellular triglycerides (Donohue, unpublished). These findings provide further evidence for an essential role of Egr-1 in ethanol-induced fatty liver and the possibility that it may initiate downstream events. They also suggest that in cultured cells, there may be post-translational regulation of Egr-1 *via* ethanol-elicited suppression of proteasome activity. While Egr-1 regulates the expression of TNF- α , it also binds to promoter regions of other genes, including that encoding transforming growth factor- β (TGF- β), which has a major role in hepatic fibrosis^[28]. Thus, Egr-1 may not only be a major factor in steatosis, but also in the more advanced stages of alcohol-induced liver injury, as suggested by Pritchard and Nagy^[20].

Alcohol-elicited steatosis: What is the actual toxin?

The preceding sections have described the molecular

mechanisms by which ethanol consumption disrupts hepatic lipid metabolism, resulting in fatty liver. As stated earlier, an evolving concept that is gaining acceptance is that certain accumulated fatty acids are toxic to the liver, but that their toxicity is blunted by esterification with glycerol to form triacylglycerols (triglycerides). Ironically, triglyceride accumulation is the principal means by which fatty liver is quantified. Thus the question of whether there is a generalized toxicity of accumulated fatty acids or that specific fatty acids are hepatotoxic is important in determining whether alcoholics are at risk for more advanced disease. Recent work by Yamaguchi *et al*^[30,31] used antisense oligonucleotide (ASO) to block the synthesis of diacylglycerol acyltransferase (DAG), thereby inhibiting triglyceride synthesis. Blockade of DAG, which catalyzes the final step in triglyceride synthesis, reduced hepatic steatosis in these animals when they were fed a methionine-choline-deficient diet to induce NASH. However, such treatment with the ASO exacerbated liver injury to cause fibrosis, despite the fact that TNF- α levels were decreased, adiponectin levels were increased, and insulin sensitivity was improved. The explanation for these findings is that the prevention of triglyceride synthesis enhanced the intracellular levels of free fatty acids in the liver. While the specific fatty acids were not identified, the fact that enhanced lipid peroxidation occurred in liver-injured animals suggests that accumulation of unsaturated fatty acids would most likely be incriminated in causing further liver damage. With regard to ethanol-elicited steatosis, there is a substantial body of evidence that unsaturated fatty acids from corn oil or fish oil cause greater liver damage than saturated fatty acids when either of these are fed in combination with alcohol.

CONCLUSION

The foregoing review has summarized both the formerly and currently accepted models of alcohol-induced fatty liver. In summary, ethanol consumption causes activation of SREBP-1, which induces genes involved in lipid biosynthesis. Conversely, ethanol consumption down-regulates the PPAR- α transcription factor, which regulates enzymes involved in fatty acid oxidation, and simultaneously prevents the import of fatty acids into the mitochondrion for oxidation. The regulation of Egr-1 by ethanol is a less well characterized but an important area of investigation, as its rapid induction may well be upstream of the latter two factors or it may exert coordinate regulation along with SREBP-1 and PPAR- α . Finally, it should be emphasized that in sections of this review, comparisons of ASH were made to other fatty liver diseases, including NASH. The latter was used simply as an analogous disorder, but there was no intent to imply that the two (ASH and NASH) are the same. Clearly, further investigations are warranted into the pathophysiology of ethanol-induced steatosis, but recent investigations have demonstrated considerable progress toward therapeutic measures. These latter discoveries will most certainly prompt further ones in preventing or abating liver damage caused by alcohol abuse.

REFERENCES

- 1 **Zhou Z**, Wang L, Song Z, Lambert JC, McClain CJ, Kang YJ. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. *Am J Pathol* 2003; **163**: 1137-1146
- 2 **Naveau S**, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. *Hepatology* 1997; **25**: 108-111
- 3 **Fehér J**, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). *J Int Med Res* 2003; **31**: 537-551
- 4 **Lieber CS**. New pathway of ethanol metabolism in the liver. *Gastroenterology* 1970; **59**: 930-937
- 5 **Lieber CS**. Hepatic, metabolic and toxic effects of ethanol: 1991 update. *Alcohol Clin Exp Res* 1991; **15**: 573-592
- 6 **Lieber CS**, DeCarli LM. Hepatotoxicity of ethanol. *J Hepatol* 1991; **12**: 394-401
- 7 **Lieber CS**, Savolainen M. Ethanol and lipids. *Alcohol Clin Exp Res* 1984; **8**: 409-423
- 8 **Carrasco MP**, Jiménez-López JM, Segovia JL, Marco C. Comparative study of the effects of short- and long-term ethanol treatment and alcohol withdrawal on phospholipid biosynthesis in rat hepatocytes. *Comp Biochem Physiol B Biochem Mol Biol* 2002; **131**: 491-497
- 9 **Carrasco MP**, Marco C, Segovia JL. Chronic ingestion of ethanol stimulates lipogenic response in rat hepatocytes. *Life Sci* 2001; **68**: 1295-1304
- 10 **You M**, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element binding protein (SREBP). *J Biol Chem* 2002; **277**: 29342-29357
- 11 **Galli A**, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. *J Biol Chem* 2001; **276**: 68-75
- 12 **Tuma DJ**, Hoffman T, Sorrell MF. The chemistry of acetaldehyde-protein adducts. *Alcohol Alcohol Suppl* 1991; **1**: 271-276
- 13 **You M**, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. *Am J Physiol Gastrointest Liver Physiol* 2004; **287**: G1-G6
- 14 **Xu A**, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest* 2003; **112**: 91-100
- 15 **Fischer M**, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. *J Biol Chem* 2003; **278**: 27997-28004
- 16 **Crabb DW**, Liangpunsakul S. Alcohol and lipid metabolism. *J Gastroenterol Hepatol* 2006; **21** Suppl 3: S56-S60
- 17 **You M**, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. *Gastroenterology* 2004; **127**: 1798-1808
- 18 **Lin HZ**, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese leptin deficient mice. *Nat Med* 2000; **6**: 998-1003
- 19 **Gashler A**, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. *Prog Nucleic Acid Res Mol Biol* 1995; **50**: 191-224
- 20 **Pritchard MT**, Nagy LE. Ethanol-induced liver injury: potential roles for egr-1. *Alcohol Clin Exp Res* 2005; **29**: 146S-150S
- 21 **Yan SF**, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. *Nat Med* 2000; **6**: 1355-1361
- 22 **Yao J**, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. *J Biol Chem* 1997; **272**: 17795-17801
- 23 **Lawler JF**, Yin M, Diehl AM, Roberts E, Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. *J Biol Chem* 1998; **273**: 5053-5059
- 24 **McMullen MR**, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. *Gastroenterology* 2005; **128**: 2066-2076
- 25 **Bae MH**, Jeong CH, Kim SH, Bae MK, Jeong JW, Ahn MY, Bae SK, Kim ND, Kim CW, Kim KR, Kim KW. Regulation of Egr-1 by association with the proteasome component C8. *Biochim Biophys Acta* 2002; **1592**: 163-167
- 26 **Genini D**, Catapano CV. Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system. *J Recept Signal Transduct Res* 2006; **26**: 679-692
- 27 **Kopf E**, Plassat JL, Vivat V, de Thé H, Chambon P, Rochette-Egly C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. *J Biol Chem* 2000; **275**: 33280-33288
- 28 **Kim SJ**, Park K, Rudkin BB, Dey BR, Sporn MB, Roberts AB. Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. *J Biol Chem* 1994; **269**: 3739-3744
- 29 **Yamaguchi K**, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology* 2007; **45**: 1366-1374
- 30 **Nanji AA**, Zhao S, Lamb RG, Dannenberg AJ, Sadrzadeh SM, Waxman DJ. Changes in cytochromes P-450, 2E1, 2B1, and 4A, and phospholipases A and C in the intragastric feeding rat model for alcoholic liver disease: relationship to dietary fats and pathologic liver injury. *Alcohol Clin Exp Res* 1994; **18**: 902-908
- 31 **Donohue TM**, Kharbanda KK, Casey CA, Nanji AA. Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease. *Alcohol Clin Exp Res* 2004; **28**: 1257-1263

S- Editor Ma N L- Editor Alpini GD E- Editor Yin DH